BIOLOGY OF SOME NEUROMUSCULAR DISORDERS
Abstract
In order to understand and possibly interfere/ treat neuromuscular disorders it is important to analyze the biological events that may be causing the disability. We illustrate such attempts on two examples of genetically determined neuromuscular diseases: 1) Duchenne muscular dystrophy (DMD), and 2) Spinal muscular atrophy (SMA).
DMD is an x-linked hereditary muscle disease that leads to progressive muscle weakness. The altered gene in DMD affects dystrophin, a muscle membrane associated proteine. Attempts were made to replace the deficient or missing gene/ protein into muscles of Duchenne children. Two main strategies were explored: 1) Myoblast and stem cell transfer and 2) Gene delivery. The possible use of methods other than the introduction of the missing gene for dystrophin into muscle fibres are based on the knowledge about the adaptive potential of muscle to different functional demands and the ability of the muscle to express a new set of genes in response to such stimuli. Stretch or overload is now known to lead to changes of gene expression in normal muscle, and the success of muscle stretch in the management of Duchenne boys is most likely to be due to such adaptive changes. Electrical stimulation of muscles is also a powerful stimulus for inducing the expression of new genes and this method too has produced beneficial effects on the progress of the disease in mice and men.
SMA is a heterogeneous group of hereditary neuromuscular disorders where the loss of lower motoneurones leads to progressive weakness and muscle atrophy. The disease subdivides into 3 forms according to the severity of the symptoms and age of onset. All three forms of SMA have been mapped to chromosome 5q11.2-13.2. Clinical features of all these forms of SMA include hypotonia shortly after birth, symmetrical muscle weakness and atrophy, finger tremor, areflexia or hyporeflexia and later contractures. In patients with SMA 1 and 2 the development of all parts of the motor unit is slower. The rate of maturation is critical for the survival of both motoneurone and muscle and that events that interfere with the time course of maturation cause both motoneurone and muscle fibre death. The proposal that the SMN gene/protein is involved in the process to developmental changes in cells and therefore crucial for their survival is put forward. The understanding of the developmental changes and their influence on motoneurone and muscle survival may help to devise therapeutic interventions. These may include a) protection of the motoneurone cell body during a critical period of its development by reducing its excitability or enhancing its defences by upregulating heat shock proteins, b) stabilizing neuromuscular junctions to enhance and prolong the retrograde influences from the muscle that affect motoneurone survival, c) protecting muscle fibres from apoptosis, as well as stimulating their maturation by activity appropriate to their younger age that results from their delayed development.
These approaches should be considered in addition to or in conjunction with possible interference with the gene and its product.
In order to understand and possibly interfere/treat neuromuscular disorders it is important to analyze the biological events that may be causing the disability. In this presentation I would illustrate such attempts on two examples of genetically determined neuromuscular diseases: 1) Duchenne muscular dystrophy, and 2) Spinal muscular atrophy.
Downloads
References
Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986; 323: 646–50.
Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919–28.
Partridge TA. Invited review: Myoblast transfer: A possible therapy for inherited myopathies? Muscle Nerve 1991; 14: 197–212.
Law PK, Goodwin TG, Li HJ, Ajamoughli G, Chen M. Myoblast transfer improves muscle genetics/structure/function and normalizes the behavior and life-span of dystrophic mice. Adv Exp Med Biol 1990; 280: 75–87.
Karpati G, Ajdukovic D, Arnold D, Gledhill RB, Guttmann R, Holland P, Koch PA, Shoubridge E, Spence D, Vanasse M, Watters GV, Abrahamowicz M, Duff C, Worton RG. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 1993; 34: 8–17.
Asakura A. Stem cells in adult skeletal muscle. Trends Cardiovasc Med 2003; 13: 123–8.
Ferrer A, Wells KE, Wells DJ. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther 2000; 7: 1439– 46.
Xiao X, Li J, Tsao YP, Dressman D, Hoffman EP, Watchko JF. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000; 74: 1436–42.
Akkaraju GR, Huard J, Hoffman EP, Goins WF, Pruchnic R, Watkins SC, Cohen JB, Glorioso JC. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. J Gene Med 1999; 1: 280–89.
Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996; 384: 349–53.
Moll J, Barzaghi P, Lin S, Bezakova G, Lochmüller H, Engvall E, Müller U, Ruegg MA. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 2001; 413: 302–7.
Pette D, Vrbová G. What does chronic electrical stimulation teach us about muscle plasticity? Muscle Nerve 1999; 22: 666–77.
Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol 2000; 150: 1399– 410.
Ozawa E, Noguchi S, Hizumo Y, Hagiwara Y, Yoshida M. From dystrophinopathy: Evolution of a concept of muscular dystrophy. Muscle Nerve 1998; 21: 421–38.
Small JV, Furst DO, Thornell LE. The cytoskeletal lattice of muscle cells. Eur J Biochem 1992; 208: 559–72.
Dangain J, Vrbová G. Muscle development in MDX mutant mice. Muscle Nerve 1984; 7: 700–4.
Dangain J, Pette D, Vrbová G. Developmental changes in succinate dehydrogenase (SDH) activity in muscle fibres from normal and dystrophic mice. J Physiol 1984; 351: 38P.
Frischknecht R, Vrbová G. Adaptation of rat extensor digitorum longus to overload and increased activity. Pflügers Arch 1991;419: 319–26.
Frischknecht R, Belverstone D, Vrbová G. The response of adult and developing rat plantaris muscle to overload. Pflügers Arch 1995; 431: 204–11.
Zhou AL, Egginton S, Brown MD, Hudlická O. Capillary growth in overloaded, hypertrophic adult rat skeletal muscle: an ultrastructural study. Anat Rec 1998; 252: 49–63.
Goldspink G, Scutt A, Loughna PT, Wells DJ, Jaenicke T, Gerlach GF. Gene expression in skeletal muscle in response to stretch and force generation. Am J Physiol 1992; 262: R356–63.
Goldspink G. Selective gene expression during adaptation of muscle in response to different physiological demands. Comp Biochem Physiol B Biochem Mol Biol 1998; 120: 5–15.
Goldspink G. Gene expression in skeletal muscle. Biochem Soc Trans 2002;30: 285–90.
Vrbová G. The effect of tenotomy on the speed of contraction of fast and slow mammalian muscle. J Physiol 1963; 166: 241–50.
Salmons S, Vrbová G. The influence of activity on some contractile characteristics of mammalian fast and slow muscles. J Physiol 1969; 201: 535–49.
Baldi JC, Reiser PJ. Intermediate filament proteins increase during chronic stimulation of skeletal muscle. J Muscle Res Cell Motil 1995; 16: 587–94.
Eisenberg BR, Salmons S. The reorganization of subcellular structure in muscle undergoing fast-to-slow type transformation. A stereological study. Cell Tissue Res 1981; 220: 449–71.
Chen G, Carroll S, Racay P, Dick J, Pette D, Traub I, Vrbova G, Eggli P, Celio M, Schwaller B. Deficiency in parvalbumin increases fatigue resistance in fasttwitch muscle and upregulates mitochondria. Am J Physiol Cell Physiol 2001; 281: C114–22.
Wu H, Rothermel B, Kanatous S, Rosenberg P, Naya FJ, Shelton JM, Hutcheson KA, DiMaio JM, Olson EN, Bassel-Duby R, Williams RS. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J 2001; 20: 6414–23.
Scott OM, Hyde SA, Goddard C, Dubowitz V. Prevention of deformity in Duchenne muscular dystrophy. A prospective study of passive stretching and splintage. Physiotherapy 1981; 67: 177–80.
Hyde SA, Scott OM, Goddard CM, Dubowitz V. Prolongation of ambulation in Duchenne muscular dystrophy by appropriate orthoses. Physiotherapy 1982; 68: 105–8.
Manzur AY, Hyde SA, Rodillo E, Heckmatt JZ, Bentley G, Dubowitz V. A randomized controlled trial of early surgery in Duchenne muscular dystrophy. Neuromuscul Disord 1992; 2: 379–87.
Arahata K, Engvall E, Hayashi YK et al. Defect of laminin M in skeletal and cardiac muscles and peripheral nerve of the homozygous dystrophic dy/dy mice. Proc Japan Acad 1993; 69: 259–64.
Luthert P, Vrbová G, Ward KM. Effects of slow frequency electrical stimulation on muscles of dystrophic mice. J Neurol Neurosurg Psychiatry 1980; 43: 803–9.
Reichmann H, Pette D, Vrbová G. Effects of low frequency electrical stimulation on enzyme and isozyme patterns of dystrophic mouse muscle. FEBS Lett 1981; 128: 55–8.
Reichmann H, Pette D, Vrbová G. Electrostimulation-induced changes in the enzyme activity pattern of dystrophic mouse muscles. Acta Histochem Suppl 1983; 28: 125–7.
Scott OM, Hyde SA, Vrbová G, Dubowitz V. Therapeutic possibilities of chronic low frequency electrical stimulation in children with Duchenne muscular dystrophy. J Neurol Sci 1990; 95: 171–82.
Zupan A. Long-term electrical stimulation of muscles in children with Duchenne and Becker muscular dystrophy. Muscle Nerve 1992; 15: 362–7.
Zupan A, Gregoric M, Valencic, Vandot S. Effects of electrical stimulation on muscles of children with Duchenne and Becker muscular dystrophy. Neuropediatrics 1993; 24: 189–92.
Berridge MJ, Dupont C. Spatial and temporal signalling by calcium. Curr Opin Cell Biol 1994; 6: 267–74.
Heimann P, Augustin M, Wieneke S, Heising S, Jockusch H. Mutual interference of myotonia and muscular dystrophy in the mouse: A study on ADRMDX double mutants. Neuromuscular Disord 1998; 8: 551–60.
Kramer R, Lochmuller H, Abicht A, Rudel R, Brinkmeier H. Myotonic ADRMDX mutant mice show less severe muscular dystrophy than MDX mice. Neuromuscular Disord 1998; 8: 542–50.
Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978; 15: 409–13.
Dubowitz V. Muscle disorders in childhood. Major Probl Clin Pediatr 1978; 16: 1–282.
Hausmanowa-Petrusewicz I, Fidziańska A. The clinical features of spinal infantile and juvenile muscular atrophy. In: Gamstorp I, Sarnat HB eds. Progressive spinal muscular atrophies. New York: Raven Press, 1984: 31–42.
Brzustowicz LM, Lehner T, Castilla LH et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990; 344: 540–1.
Melki J, Abdelhak S, Sheth P et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 1990; 344: 767–8.
Lefebvre S, Burglen L, Reboullet S et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155–65.
Lefebvre S, Burlet P, Liu Q et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16: 265–9.
Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996; 15: 3555–65.
Fischer U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 1997; 90: 1023–9.
Young PJ, Man NT, Lorson CL, Le TT, Androphy EJ, Burghes AH, Morris GE. The exon 2b region of the spinal muscular atrophy protein, SMN, is involved in self-association and SIP1 binding. Hum Mol Genet 2000; 9: 2869–77.
Malamud W. Infantile progressive muscular atrophy. In: Minckler J ed. Pathology of the nervous system. McGrow Book Company, 1968: 45–54.
Malinsky J. Ultrastructural changes of cell elements during the differentiation of neuroblasts and glioblasts in human spinal cord. Acta Univ Olumunic Faculty Med 1972; 64: 183–93.
Buchthal F, Olsen PZ. Electromyography and muscle biopsy in infantile spinal muscular atrophy. Brain 1970; 93: 15–30.
Hausmanowa-Petrusewicz I, Karwańska A. Electromyographic findings in different forms of infantile and juvenile proximal spinal muscular atrophy. Muscle Nerve 1986; 9: 37–46.
Hausmanowa-Petrusewicz I, Friedman A, Kowalski J, Skalski M. Spontaneous motor unit firing in spinal muscular atrophy of childhood. Electromyogr Clin Neurophysiol 1987; 27: 259–64.
Navarrete R, Vrbová G. Differential effect of nerve injury at birth on the activity pattern of reinnervated slow and fast muscles of the rat. J Physiol 1984; 351: 675–85.
Drac H. Histological changes in peripheral nerves in spinal Werdnig-Hoffmann muscular atrophy. Neuropatol Pol 1977; 15: 1–16 (Polish).
Greenfield JC, Stern RO. The anatomical identity of the Werdnig-Hoffmann and Oppenheim forms of infantile muscular atrophy. Brain 1927; 50: 652–86.
Krajewska G, Hausmanowa-Petrusewicz I. Abnormal nerve conduction velocity as a marker of immaturity in childhood muscle spinal atrophy. Folia Neuropathol 2002; 40: 67–74.
Sarnat HB. Pathology of spinal muscular atrophy. In: Gamstorp I, Sarnat HB, eds. Progressive Spinal Muscular Atrophy. New York: Raven Press, 1974: 91– 110.
Fidziańska A, Goebel HH, Warlo I. Acute infantile spinal muscular atrophy. Muscle apoptosis as a proposed pathogenetic mechanism. Brain 1990; 113: 433–45.
Sarnat HB. Vimentin and desmin in maturing skeletal muscle and developmental myopathies. Neurology 1992; 42: 1616–24.
Goebel HH, Bornemann A. Desmin pathology in neuromuscular diseases. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64: 127–35.
Hamburger V. The developmental history of the motor neuron. Neurosci Res Program Bull 1977; 15: 1–37.
Lowrie MB, Vrbová G. Dependence of postnatal motoneurones on their targets: review and hypothesis. Trends Neurosci 1992; 15: 80–4.
Navarrete R, Vrbová G. Activity-dependent interactions between motoneurones and muscles: their role in the development of the motor unit. Prog Neurobiol 1993; 41: 93–124.
Greensmith L, Vrbová G. Motoneurone survival: a functional approach. Trends Neurosci 1996; 19: 450–5.
Greensmith L, Hasan HI, Vrbová G. Nerve injury increases the susceptibility of motoneurons to N-methyl-D-aspartate-induced neurotoxicity in the developing rat. Neuroscience 1994a; 58: 727–33.
Greensmith L, Mentis GZ, Vrbová G Blockade of N-methyl-D-aspartate receptors by MK-801 (dizocilpine maleate) rescues motoneurones in developing rats. Dev Brain Res 1994b; 81: 162–70.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
